Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cytokines and solid tumors]

F Triebel1, B Escudier

  • 1Service d'hémato-immunologie, INSERM U 333, Institut Gustave-Roussy, Villejuif.

La Revue Du Praticien
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Cytokines, such as interleukin-2 (IL-2), are crucial for stimulating anti-tumoral responses in cancer treatment. This review details their development and clinical trial outcomes for solid tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.

ESMO open·2024
Same author

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.

ESMO open·2024
Same author

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.

ESMO open·2024
Same author

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology.

ESMO open·2023
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Cytokines are key regulators of cell proliferation and differentiation in hematopoiesis and immunopoiesis.
  • They play a vital role in stimulating effector cells for anti-tumoral immune responses.
  • Cytokine-based therapies are increasingly explored for solid tumor treatment.

Purpose of the Study:

  • To detail the preclinical and clinical development process of cytokines in oncology.
  • To use Interleukin-2 (IL-2) as a specific example to illustrate these developmental stages.
  • To present and discuss the outcomes of clinical trials involving cytokines like Interferon (IFN) and IL-2.

Main Methods:

  • Review of preclinical research on cytokine mechanisms in cancer.
  • Analysis of clinical trial data for cytokines in solid tumor treatment.

Related Experiment Videos

  • Case study focusing on the development pathway of IL-2.

    • Main Results:

    • Cytokines demonstrate potential in enhancing anti-tumoral immune responses.
    • Clinical trials with Interferon (IFN) and IL-2 have yielded specific results in solid tumor treatment.
    • The development pathway involves rigorous preclinical and clinical evaluation.

    Conclusions:

    • Cytokines are valuable therapeutic agents in the oncology landscape.
    • IL-2 serves as a representative model for cytokine drug development.
    • Further research and clinical application of cytokines are warranted for solid tumors.